Redx Pharma

Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease

Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 — Alderley Park, UK — Redx Pharma, the clinical-stage, small molecule biotechnology company focused on tackling fibrosis, today announces the presentation of additional results from an RXC008 Phase 1 clinical…

Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week

Presentation submission wins Top Abstract Prize The oral presentation, entitled “RXC008: First-in-Class Gastrointestinal-Targeted Potent Pan-ROCK Inhibitor for Treatment of Fibrostenotic Crohn’s Disease”, was delivered on Monday 14 October, during the session: IBD: New horizons in medical treatment – Part 1 RXC008 is currently in phase 1 clinical development where results from healthy volunteer cohorts are…